Ozempic‑like Drug Semaglutide Extends Lifespan and Improves Health in Older Mice

In a recent study, the GLP‑1 agonist semaglutide—commercially known as Ozempic—was administered to older, healthy mice. The treated animals lived longer than controls and displayed marked improvements in memory, muscle strength, and blood‑sugar regulation. Researchers also noted favorable shifts in several biological markers of aging, such as reduced oxidative stress and enhanced cellular repair pathways. Importantly, the benefits exceeded those achieved by calorie restriction alone, suggesting semaglutide activates a distinct biological route linked to longevity. The findings point to the potential of GLP‑1 drugs as a novel class of therapeutics that could target age‑related decline beyond their established role in diabetes management.